P0665 - Effect of Glucagon-Like Peptide-1 Receptor Agonists on Quality of Bowel Preparation for Colonoscopy: A Matched Case-Control Study

Rabih Ghazi, MD¹, Rasha Abi Radi Abou Jaoudeh, MD², Karl Akiki, MD¹, Jaclyn Levendusky, BS³, Kimberly Tena Diaz, DO⁴, Krysta Contino, MD⁵, Apeksha Shah, MD⁶, Christina Tofani, MD, FACG⁷, Rachel Frank, MD⁸, Adib Chaaya, MD^9
1Cooper University Hospital, Philadelphia, PA; ²Cleveland Clinic Foundation, Cleveland, OH; ³Cooper Medical School of Rowan University, Camden, NJ; ⁴Cooper University Health Care, Camden, NJ; ⁵Digestive Health Institute at Cooper University Hospital, Mount Laurel, NJ; ⁶Digestive Health Institute at Cooper University Hospital, Mt. Laurel, NJ; ⁷Digestive Health Institute at Cooper University Hospital, Camden, NJ; ⁸Cooper University Hospital, Mt. Laurel, NJ; ⁹Cooper Health Gastroenterology, Camden, NJ

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for their anti-glycemic and weight loss effects. Delayed gastric emptying promotes early satiety and weight loss. However, recent studies have raised concerns regarding the impact of GLP-1RA on bowel preparation quality, but supporting data remains limited. This study evaluates the effect of GLP-1RA on bowel preparation quality and procedure success in patients undergoing colonoscopy.

Methods: This retrospective chart review included patients on GLP-1RA for diabetes or weight management who underwent colonoscopy or esophagogastroduodenoscopy (EGD) + colonoscopy between October 1, 2018, and October 1, 2023. Patients who discontinued GLP-1RA at least one week before the procedure and those with altered gastrointestinal anatomy were excluded from the study. GLP-1RA patients were matched to controls (not on GLP-1RA) by age group, BMI classification, and history of diabetes and gastroparesis. Primary outcome was bowel preparation quality. Secondary outcomes included procedure success rate, procedure time, and adverse event rates. Outcomes were compared using Pearson's chi-square or Fisher’s exact test for categorical variables and Student’s t-test or Wilcoxon rank-sum test for continuous variables.

Results: A total of 214 procedures were included (GLP-1RA 107 and Control 107). The GLP1-RA group had comparable baseline characteristics to the control group except for reflux disease (62.6% vs 43.9%; p=0.006), use of antisecretory medications (56.1% vs 40.2%; p=0.02), and ASA class (52.3% vs 32.7% ASA class 2; p=0.019), respectively. Bowel preparation quality was comparable in GLP1-RA and control groups (excellent in 27.1% vs 29.9%, good in 64.5% vs 57.9%, and poor in 8.4% vs 12.2% respectively; p=0.536). Both groups had similar procedure success rates (91.6% in GLP1-RA vs 92.5% in control; p=0.800) and procedure times (p=0.156). No statistically significant difference was observed in overall adverse events (11.2% in GLP-1RA vs 14.9% in control; p=0.418).

Discussion: GLP-1RA did not affect bowel preparation quality, procedure success rate, or procedure time for colonoscopy. These findings suggest that GLP-1RA do not need to be held in patients with planned colonoscopy.


Disclosures:


Rabih Ghazi, MD¹, Rasha Abi Radi Abou Jaoudeh, MD², Karl Akiki, MD¹, Jaclyn Levendusky, BS³, Kimberly Tena Diaz, DO⁴, Krysta Contino, MD⁵, Apeksha Shah, MD⁶, Christina Tofani, MD, FACG⁷, Rachel Frank, MD⁸, Adib Chaaya, MD⁹. P0665 - Effect of Glucagon-Like Peptide-1 Receptor Agonists on Quality of Bowel Preparation for Colonoscopy: A Matched Case-Control Study, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.